LivingGLP1
parallel randomized trial

S003087

Design

Randomized
65
Start year
Treatment
2 weeks, follow-up 2 weeks
Countries
China (1 sites)
Sponsor
(not reported)
Eligibility
age over 20; T2D 1 year or more; HbA1c 8 to 14 percent; BMI 45 or less; metformin plus MDI

Conduct and analysis

Blinding
open label
Sequence generation
computer
Allocation concealment
not reported
Outcome adjudication
not reported
Primary estimand
not stated
Analysis population
completers
Missing data
completers only

Arms

ArmTreatmentBackgroundRandomizedAnalyzedCompleted treatment
A1Liraglutide subcutaneous once daily, flexible dose: 1.2 or 1.8 mg by tolerability
CSII plus liraglutide
CSII insulin aspart and metformin 2000 mg daily; lifestyle: standard3330
A2Standard care or no added treatment
CSII
CSII insulin aspart and metformin 2000 mg daily; lifestyle: standard3230

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.
CharacteristicStatisticLiraglutide subcutaneous once daily, flexible dose: 1.2 or 1.8 mg by tolerability
A1
Standard care or no added treatment
A2
agemedian (years)50.049.0
ageq1 (years)42.542.5
ageq3 (years)63.561.0
bmimean (kg/m2)29.429.0
bmisd (kg/m2)3.44.2
diabetes durationmedian (years)9.06.0
diabetes durationq1 (years)2.03.0
diabetes durationq3 (years)17.513.0
established cvdn96
femalen37
hba1cmedian (percent)9.310.0
hba1cq1 (percent)8.58.8
hba1cq3 (percent)13.012.0
insulin dosemedian (U/kg/day)0.590.62
insulin doseq1 (U/kg/day)0.550.57
insulin doseq3 (U/kg/day)0.640.65
sbpmean (mmHg)140.0135.3
sbpsd (mmHg)18.117.4
uacr: microalbuminurian812
weightmean (kg)85.582.4
weightsd (kg)9.811.8

Results

11 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
Body weight change in kilograms (diabetes) (3 lines; O02)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
2A1change-2.5 kg0.530not stated; completers; R0019704:Results
2A2change0.2 kg1.130not stated; completers; R0019704:Results
2A2 vs A1md2.7 kgnot stated; completers; R0019704:Results
Level 2 or 3 hypoglycemia (participants) (2 lines; O04)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / 30not stated; completers; R0019704:Results
A2events0 / 30not stated; completers; R0019704:Results
Percent body weight change (3 lines; O10)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
2A1percent change-2.93 percent30not stated; completers; R0019704:Results
2A2percent change0.24 percent30not stated; completers; R0019704:Results
2A2 vs A1md3.17 percentnot stated; completers; R0019704:Results
Nausea (1 lines; O27A)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events9 / 30not stated; completers; R0019704:Methods
Vomiting (1 lines; O27B)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events1 / 30not stated; completers; R0019704:Methods
Diarrhea (1 lines; O27C)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events1 / 30not stated; completers; R0019704:Methods